Adult Dosing
Acute migraine attacks with or without aura
- 1 or 2.5 mg PO as single dose; may repeat once after 4 hours, if headache occurs
- Max: 5 mg/24 hrs
- Note: Safety of treating, on average, more than 4 headaches in a 30-day period has not been established
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
[Outline]
Renal Dose Adjustment (Based on CrCl )
- Mild to moderate Renal impairment (18-369 mL/min: Use a lower initial dose. (Max: 2.5 mg/24 hrs)
- Severe renal impairment (< 30 mL/min): Contraindicated
Hepatic Dose Adjustment
- Mild to moderate impairment: Use a lower initial dose. (Max: 2.5 mg/day)
- Severe Hepatic Impairment: Contraindicated
- Do not use if migraine has been detected
- Naratriptan should not be given when risk factors for CAD are present (e.g. hypertension, hypercholesterolemia, diabetes, strong family history of CAD, female with surgical or physiological menopause)
- Serious adverse cardiac events, including acute MI, arrhythmias, and death, have been reported within a few hours following administration
- Coronary vasospasm has occured in patient without any cardiac history or Coronary artery disease.
- Patient with sign and symptoms of angina should evaluate the dose with presence of CAD or predisposition to Prinzmetal’s variant angina before receiving additional medicine, monitor ECG if symptoms recur
- Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported and some events resulted to be fatal. patient with acute migraine are risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack)
- Peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea have been reported
- Potentially life-threatening serotonin syndrome may occur with coadministration of serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
- Increase in blood pressure have been reported very rarely, contraindicated in patient with uncontrolled hypertension
- Sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw have been reported. Patients with such signs or symptoms should be evaluated for the presence of CAD or predisposition to Prinzmetal’s variant angina before receiving additional dose of medication and monitor ECG
- Exclude underlying cardiovascular disease, supervise first dose, and consider monitoring ECG in patients with likelihood of unrecognized coronary disease (eg, postmenopausal women, men over age 40, hypertension, hypercholesterolemia, obesity, diabetes, smokers, strong family history)
Cautions: Use cautiously in
- Hypertension
- Renal impairment
- Hepatic impairment
- Diabetes Mellitus
- Concomitant use with SSRI's serotonin syndrome possible
- Elderly patients
Pregnancy Category:C
Breastfeeding: An alternate drug may be preferred, especially while nursing a newborn or preterm infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 8 January 2011). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Amerge 2.5 MG TABS [Box] (GLAXO SMITH KLINE)
9 mg = $304
27 mg = $885 - Amerge 1 MG TABS [Box] (GLAXO SMITH KLINE)
9 mg = $290
27 mg = $829.95
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Amerge 1 MG Oral Tablet
Ingredient(s): Naratriptan
Imprint: GX;CE3
Color(s): White
Shape: Oval
Size (mm): 13.00
Score: 1
Inactive Ingredient(s): croscarmellose sodium / hypromellose / lactose / magnesium stearate / cellulose, microcrystalline / triacetin / titanium dioxide
Drug Label Author:
GlaxoSmithKline LLC
DEA Schedule:
Non-Scheduled
Drug Name: Amerge 2.5 MG Oral Tablet
Ingredient(s): Naratriptan
Imprint: GX;CE5
Color(s): Green
Shape: Oval
Size (mm): 13.00
Score: 1
Inactive Ingredient(s): croscarmellose sodium / hypromellose / lactose / magnesium stearate / cellulose, microcrystalline / triacetin / titanium dioxide / ferric oxide yellow / fd&c blue no. 2 / indigotindisulfonate sodium
Drug Label Author:
GlaxoSmithKline LLC
DEA Schedule:
Non-Scheduled
